NCT07258914 Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)
| NCT ID | NCT07258914 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Center Guillaume Régnier |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2024-12-19 |
| Primary Completion | 2026-02-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2024-12-19 with a primary completion date of 2026-02-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Depression is a common complication of Autism Spectrum Disorder (ASD): it is four times more prevalent in people with ASD than in the general population. However, treating depression in people with ASD is complicated by the lack of guidelines. Antidepressants appear to be less effective and less well tolerated than in the general population. rTMS (repetitive transcranial magnetic stimulation) is a technique that stimulates the brain in a painless and non-invasive way. This technique is well tolerated and has very few side effects (headaches, fatigue). It is now used routinely in clinical practice to treat resistant depression, with satisfactory results. A few studies using rTMS in depression in people with ASD have shown encouraging results and avenues for improvement. It could therefore be interesting to conduct a therapeutic study with rTMS on depression in people with ASD, following the avenues for improvement proposed by previous studies. The main objective is to evaluate the effectiveness of rTMS in depressed patients with ASD by looking at changes in mood before and after treatment. The investigator will also look at the effects on executive and attentional functions and repetitive behaviors, as well as treatment tolerance.
Eligibility Criteria
Inclusion Criteria: * Patient with a diagnosis of ASD validated by a psychiatrist or line 2 * Patient aged 18 to 65... * Patients suffering from EDM (MADRS greater than 20) * No change in treatment in the month prior to inclusion * Patients affiliated with or entitled to social security * Patients who have received informed information about the study and have signed a consent form to participate in the study Exclusion Criteria: * Patients with psychiatric comorbidity (decompensated manic state, schizophrenic disorder) * Pregnancy at the time of inclusion * Patients with contraindications to rTMS and MRI (history of epilepsy, neurological stimulator, pacemaker, cardiac defibrillator, cardiac prosthesis, vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metal fragments in the eyes, claustrophobia) * Adults under legal protection (legal guardianship, curatorship, trusteeship), persons deprived of their liberty, persons hospitalised under compulsion (SDT, SDRE).
Contact & Investigator
Cécilia NAUCZYCIEL, Doctor
PRINCIPAL INVESTIGATOR
Centre Hospitalier Guillaume Régnier
Frequently Asked Questions
Who can join the NCT07258914 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07258914 currently recruiting?
Yes, NCT07258914 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hospital Center Guillaume Régnier to inquire about joining.
Where is the NCT07258914 trial being conducted?
This trial is being conducted at Rennes, France.
Who is sponsoring the NCT07258914 clinical trial?
NCT07258914 is sponsored by Hospital Center Guillaume Régnier. The principal investigator is Cécilia NAUCZYCIEL, Doctor at Centre Hospitalier Guillaume Régnier. The trial plans to enroll 25 participants.